Reviewing the Australasian Society of Clinical Immunology and Allergy (ASCIA) guidelines and considering symptom severity and frequency can help guide the most appropriate treatment approach for allergic rhinitis in an individual patient.1 Dymista® 125/50 (azelastine/fluticasone propionate) combination nasal spray is a first-line option for persistent, mild and moderate-to-severe allergic rhinitis symptoms.1,2
PBS Information: This product is not listed on the PBS.
PLEASE REVIEW PRODUCT INFORMATION AVAILABLE HERE, BEFORE PRESCRIBING.
References: 1. ASCIA Allergic Rhinitis Clinical Update. Information for Healthcare Professionals, 2020. 2. Dymista® 125/50 Approved Product Information.
Want more information on Dymista® or other Viatris products and services?
Privacy Notice | Terms of Use | Cookie Notice | Contact Us
Dymista® is a Viatris registered trademark. Copyright © 2022 Viatris Inc. All rights reserved. Viatris Pty Ltd. ABN 29 601 608 771. Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point, NSW 2000, Australia. Ph: 1800 314 527. DYM-2022-0382. May 2022.
The Viatris Privacy Notice describes our collection, use, disclosure, and retention of Personal Data. The Notice also explains the ways in which you may, under applicable laws, be able to control our processing of your Personal Data and exercise other rights.
